Leerink Partnrs Analysts Boost Earnings Estimates for CLOV

Clover Health Investments, Corp. (NASDAQ:CLOV) – Equities research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for shares of Clover Health Investments in a research note issued on Monday, October 20th. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings per share of ($0.03) for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Clover Health Investments’ current full-year earnings is ($0.12) per share. Leerink Partnrs also issued estimates for Clover Health Investments’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.12) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at $0.07 EPS, FY2028 earnings at $0.12 EPS and FY2029 earnings at $0.19 EPS.

A number of other equities research analysts have also recently commented on the company. Canaccord Genuity Group dropped their target price on Clover Health Investments from $4.50 to $4.10 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Clover Health Investments in a research report on Wednesday, October 8th. UBS Group dropped their target price on Clover Health Investments from $4.50 to $3.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Finally, Leerink Partners set a $3.00 price objective on Clover Health Investments and gave the stock a “market perform” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.03.

Clover Health Investments Stock Down 4.3%

NASDAQ:CLOV opened at $3.08 on Thursday. Clover Health Investments has a 52 week low of $2.12 and a 52 week high of $4.87. The stock has a market capitalization of $1.58 billion, a PE ratio of -38.50 and a beta of 2.10. The stock’s 50-day moving average price is $2.82 and its 200-day moving average price is $3.02.

Institutional Investors Weigh In On Clover Health Investments

Institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its holdings in Clover Health Investments by 80.5% in the 1st quarter. Rhumbline Advisers now owns 7,085 shares of the company’s stock worth $25,000 after buying an additional 3,160 shares during the last quarter. Clarity Wealth Advisors LLC purchased a new position in Clover Health Investments in the 2nd quarter worth approximately $28,000. Fifth Third Bancorp purchased a new position in Clover Health Investments in the 2nd quarter worth approximately $28,000. Perigon Wealth Management LLC purchased a new position in Clover Health Investments in the 1st quarter worth approximately $36,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Clover Health Investments in the 1st quarter worth approximately $37,000. 19.77% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Clover Health Investments

In other news, Director Anna U. Loengard acquired 26,500 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were bought at an average cost of $2.59 per share, for a total transaction of $68,635.00. Following the acquisition, the director owned 29,610 shares in the company, valued at approximately $76,689.90. This represents a 852.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 24.07% of the company’s stock.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.